| scholarly article | Q13442814 |
| P2093 | author name string | Gregory E Wilding | |
| Rocco C Venuto | |||
| Kimberly Clark | |||
| Kathleen M Tornatore | |||
| Calvin J Meaney | |||
| Karen Shin | |||
| Aijaz Gundroo | |||
| Shirley S Chang | |||
| Gerald J Fetterly | |||
| Joshua Prey | |||
| Louise M Cooper | |||
| Vanessa Gray | |||
| P2860 | cites work | A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 |
| Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity | Q33370034 | ||
| Validity and reliability of a novel immunosuppressive adverse effects scoring system in renal transplant recipients | Q33773992 | ||
| Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry | Q34365272 | ||
| Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients | Q34573738 | ||
| Enterohepatic circulation: physiological, pharmacokinetic and clinical implications | Q34774063 | ||
| The influence of sex on pharmacokinetics | Q35049301 | ||
| Mycophenolic Acid Pharmacodynamics and Pharmacokinetics Provide a Basis for Rational Monitoring Strategies | Q35129548 | ||
| The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance | Q35956193 | ||
| Dialogues on diversifying clinical trials: successful strategies for engaging women and minorities in clinical trials. | Q36204611 | ||
| Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid | Q36274069 | ||
| Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics | Q36597641 | ||
| Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity? | Q36727064 | ||
| Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies | Q37272044 | ||
| New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation | Q37523152 | ||
| Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation | Q37670499 | ||
| The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease | Q37818144 | ||
| Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. | Q37824525 | ||
| Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing. | Q38032010 | ||
| Sex and gender in adverse drug events, addiction, and placebo | Q38048663 | ||
| Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update | Q38208983 | ||
| Sex differences in drug conjugation and their consequences for drug toxicity. Sulfation, glucuronidation and glutathione conjugation | Q39587524 | ||
| Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. | Q42612839 | ||
| Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial | Q42621907 | ||
| Enteric-coated mycophenolate sodium. | Q42925114 | ||
| Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients | Q43463833 | ||
| Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid | Q43569296 | ||
| In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil | Q43760215 | ||
| Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients | Q44316340 | ||
| Race and drug formulation influence on mycophenolic acid pharmacokinetics in stable renal transplant recipients | Q44447188 | ||
| Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients | Q44663050 | ||
| Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats | Q44772834 | ||
| Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients | Q44789623 | ||
| The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy | Q46055999 | ||
| Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial | Q46301570 | ||
| Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. | Q46427135 | ||
| Differential effects of cyclosporine and tacrolimus on mycophenolate pharmacokinetics in patients with impaired kidney function | Q46512740 | ||
| Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation | Q46622999 | ||
| Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation | Q46816110 | ||
| Reduced exposure to calcineurin inhibitors in renal transplantation | Q46840533 | ||
| Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. | Q46923376 | ||
| Simultaneous determination of cortisol, dexamethasone, methylprednisolone, prednisone, prednisolone, mycophenolic acid and mycophenolic acid glucuronide in human plasma utilizing liquid chromatography-tandem mass spectrometry | Q46956941 | ||
| Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation | Q46972643 | ||
| Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium | Q48629550 | ||
| Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2010 Data Report | Q60307956 | ||
| RS-61443--a phase I clinical trial and pilot rescue study | Q67513704 | ||
| Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable | Q73927459 | ||
| Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation | Q74528702 | ||
| The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function | Q74662793 | ||
| Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group | Q78164651 | ||
| Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients | Q79294815 | ||
| Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients | Q79428999 | ||
| Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients | Q80054548 | ||
| Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice | Q81803899 | ||
| Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients | Q83136486 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 423-434 | |
| P577 | publication date | 2015-04-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients | |
| P478 | volume | 54 |
| Q28074348 | An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus |
| Q92889788 | Different Routes of Proton Pumps Inhibitors Co-Administration have Significant Impact on Mycophenolate Acid (MPA) Serum Levels in Heart Transplant Recipients |
| Q53126891 | Pharmacokinetic Variability of Mycophenolic Acid in Pediatric and Adult Patients With Hematopoietic Stem Cell Transplantation. |
| Q90497577 | Sex and the kidneys: current understanding and research opportunities |
| Q38750337 | Sex differences in transplantation |
| Q56380780 | The utility of trough mycophenolic acid levels for the management of lupus nephritis |
Search more.